LRP5 inhibition reduces arterial thrombosis in models while preserving hemostasis better than P2Y12 blockade

The study combined LRP5-knockout mice with selective small-molecule inhibition and human platelet-rich plasma experiments. LRP5-deficient animals failed to occlude the carotid artery within 30 minutes versus 21 minutes in wild-type controls, accompanied by reduced platelet and fibrin deposition. Human blood treated with the LRP5 inhibitor showed parallel decrements in collagen- and ADP-triggered aggregation under arterial shear. Critically, tail-bleeding times remained near-normal, contrasting with marked prolongation seen with equi-effective doses of established P2Y12 antagonists.

Mechanistic work revealed a previously unrecognized physical interaction between LRP5 and the P2Y12 receptor that appears necessary for receptor recycling and sustained ADP signaling. This places LRP5 downstream or parallel to current drug targets yet apparently spares the broader hemostatic functions that rely on other collagen receptors such as GPVI. The dissociation between antithrombotic efficacy and bleeding liability therefore maps to a narrower node within the platelet signaling network.

If these findings translate, LRP5-directed agents could address the persistent unmet need for intensified antithrombotic regimens in high-risk ACS or post-stent patients who currently face forced dose reductions or early discontinuation because of hemorrhage. Next steps require human phase 1 safety data and a direct comparison against ticagrelor in a large-animal arterial injury model to quantify the therapeutic window before clinical trial design.